drugset / Trial / NCT03701880

Early Use of Ivabradine in Heart Failure

NCT03701880

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the work is to Evaluate the efficacy, quality of life and safety of early addition of ivabradine to B-blocker in reduced EF heart failure patients after acute decompensation compared to the standard treatment.

Timeline

Start
2018-09-16
Primary completion
2019-12-23
Completion
2019-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivabradine Small molecule 7.5 mg
Background Bisoprolol Other / unclassified 10 mg

Indications